Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Nov:46:102592.
doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.

Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment

Fabio Giuseppe Masuccio  1 , Marianna Lo Re  2 , Antonio Bertolotto  2 , Marco Capobianco  2 , Claudio Solaro  3
Affiliations
Case Reports

Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment

Fabio Giuseppe Masuccio et al. Mult Scler Relat Disord. 2020 Nov.

Abstract

Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19.

Keywords: Anti-IL6 receptor; COVID-19; MOGAD; Monoclonal antibody; SARS-CoV-2; Tocilizumab.

PubMed Disclaimer

Conflict of interest statement

Fabio Giuseppe Masuccio and Marianna Lo Re declare no conflict of interest. Antonio Bertolotto served on the advisory boards of Alexion, Biogen, Novartis, Sanofi and/or received speaking honoraria from Alexion, Biogen, Novartis, Sanofi and grant support from Almiral, Biogen, Associazione San Luigi Gonzaga ONLUS, Fondazione per la Ricerca Biomedica ONLUS, Novartis and the Italian Multiple Sclerosis Society. Marco Capobianco received personal fees and compensation for speaking at medical meeting and participating in advisory board from Almirall, Biogen, Merck, Sanofi, Roche, Novartis. Claudio Solaro served on the advisory boards of Biogen Idec and Merck Serono. He received speaking honoraria from Bayer Schering, Biogen Idec, Merck Serono, Almirall, Teva and Genzyme. He received research grants and support from the Italian MS Society Research Foundation (Fondazione Italiana Sclerosi Multipla).

Figures

Fig. 1
Fig. 1
Timeline of tocilizumab treatment during Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
See this image and copyright information in PMC

References

    1. Capra R., Rossi N.D., Mattioli F., Romanelli G., Scarpazza C., Pia M., Cossi S. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur. J. Int. Med. 2020 - PMC - PubMed
    1. Jarius S., Ruprecht K., Kleiter I., Borisow N., Asgari N., Pitarokoili K., Pache F., Stich O., Beume L.A., Hümmert M.W., Ringelstein M., Trebst C., Winkelmann A., Schwarz A., Buttmann M., Zimmermann H., Kuchling J., Franciotta D., Capobianco M., Siebert E., Lukas C., Korporal-Kuhnke M., Haas J., Fechner K., Brandt A.U., Schanda K., Aktas O., Paul F., Reindl M., Wildemann B. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J. Neuroinflamm. 2016;13:1–45. doi: 10.1186/s12974-016-0718-0. - DOI - PMC - PubMed
    1. Toniati P., Piva S., Cattalini M., Garrafa E., Regola F., Castelli F., Franceschini F., Airò P., Bazzani C., Beindorf E.A., Berlendis M., Bezzi M., Bossini N., Castellano M., Cattaneo S., Cavazzana I., Contessi G.B., Crippa M., Delbarba A., De Peri E., Faletti A., Filippini M., Frassi M., Gaggiotti M., Gorla R., Lanspa M., Lorenzotti S., Marino R., Maroldi R., Metra M., Matteelli A., Modina D., Moioli G., Montani G., Muiesan M.L., Odolini S., Peli E., Pesenti S., Pezzoli M.C., Pirola I., Pozzi A., Proto A., Rasulo F.A., Renisi G., Ricci C., Rizzoni D., Romanelli G., Rossi M., Salvetti M., Scolari F., Signorini L., Taglietti M., Tomasoni G., Tomasoni L.R., Turla F., Valsecchi A., Zani D., Zuccalà F., Zunica F., Focà E., Andreoli L., Latronico N. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun. Rev. 2020;19 doi: 10.1016/j.autrev.2020.102568. - DOI - PMC - PubMed
    1. Whittam D.H., Karthikeayan V., Gibbons E., Kneen R., Chandratre S., Ciccarelli O., Hacohen Y., de Seze J., Deiva K., Hintzen R.Q., Wildemann B., Jarius S., Kleiter I., Rostasy K., Huppke P., Hemmer B., Paul F., Aktas O., Pröbstel A.K., Arrambide G., Tintore M., Amato M.P., Nosadini M., Mancardi M.M., Capobianco M., Illes Z., Siva A., Altintas A., Akman-Demir G., Pandit L., Apiwattankul M., Hor J.Y., Viswanathan S., Qiu W., Kim H.J., Nakashima I., Fujihara K., Ramanathan S., Dale R.C., Boggild M., Broadley S., Lana-Peixoto M.A., Sato D.K., Tenembaum S., Cabre P., Wingerchuk D.M., Weinshenker B.G., Greenberg B., Matiello M., Klawiter E.C., Bennett J.L., Wallach A.I., Kister I., Banwell B.L., Traboulsee A., Pohl D., Palace J., Leite M.I., Levy M., Marignier R., Solomon T., Lim M., Huda S., Jacob A. Treatment of MOG antibody associated disorders: results of an international survey. J. Neurol. 2020 doi: 10.1007/s00415-020-10026-y. - DOI - PMC - PubMed
    1. Wynford-Thomas R., Jacob A., Tomassini V. Neurological update: MOG antibody disease. J. Neurol. 2019;266:1280–1286. doi: 10.1007/s00415-018-9122-2. - DOI - PMC - PubMed

Substances

LinkOut - more resources